Authors: Spanjaart, Anne Mea; Ljungman, Per; de La Camara, Rafael; Tridello, Gloria; Ortiz-Maldonado, Valentin; Urbano-Ispizua, Alvaro; Barba, Pere; Kwon, Mi; Caballero, Dolores; Sesques, Pierre; Bachy, Emmanuel; Di Blasi, Roberta; Thieblemont, Catherine; Calkoen, Friso; Mutsaers, Pim; Maertens, Johan; Giannoni, Livia; Nicholson, Emma; Collin, Matthew; Vaz, Carlos Pinho; Metafuni, Elisabetta; Martinez-Lopez, Joaquin; Dignan, Fiona L.; Ribera, Josep-Maria; Nagler, Arnon; Folber, Frantisek; Sanderson, Robin; Bloor, Adrian; Ciceri, Fabio; Knelange, Nina; Ayuk, Francis; Kroger, Nicolaus; Kersten, Marie Jose; Mielke, Stephan
Venue: Blood
Type: Publication
Abstract: Abstract Background The ongoing Coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is having an enormous impact on society worldwide and is especially posing a threat to health in vulnerable patients, such as patients with immune deficiencies. It is expected that patients who received Chimeric Antigen Receptor T-cell (CAR T-cell) therapy for hematologic malignancies are at risk for poor outcomes after COVID-19 due to their severely immunocompromised state caused by prior cum...
(read more)
Impact:
8.185042E-8
7.528686E-9
99
86
/ Attention:
0
10
Topics: 
Internal medicine
Immunology
Oncology
Loading (it may take a couple of seconds)...
Loading (it may take a couple of seconds)...
Loading (it may take a couple of seconds)...
Loading (it may take a couple of seconds)...